Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Realm Therapeutics PLC    PURI   GB00B3XBCR18

REALM THERAPEUTICS PLC (PURI)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
07/09/2018 07/10/2018 07/11/2018 07/12/2018 07/13/2018 Date
38.5(c) 38.5(c) 40(c) 38(c) 38(c) Last
0 46 856 20 638 5 637 981 1 387 Volume
0.00% 0.00% +3.90% -5.00% 0.00% Change
More quotes
Financials (GBP)
Sales 2018 0,81 M
EBIT 2018 -
Net income 2018 -
Finance 2018 15,5 M
Yield 2018 -
Sales 2019 0,81 M
EBIT 2019 -
Net income 2019 -
Finance 2019 2,21 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 35,4x
EV / Sales2019 51,8x
Capitalization 44,2 M
More Financials
Company
Realm Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the development of novel therapeutics for immunemediated diseases.It focusThe company was founded on April 21, 2006 and is headquartered in Malvern, PA. 
More about the company
Latest news on REALM THERAPEUTICS PLC
07/14REALM THERAPEUTICS : Announces Publication of Pre-Clinical Study Demonstrating C..
AQ
07/12REALM THERAPEUTICS : Announces U.S. SEC Declares Registration Statement Effectiv..
AQ
07/10REALM THERAPEUTICS : Pre-Clinical Study in Atopic Dermatitis
PU
07/05REALM THERAPEUTICS : Patent Issued for Methods and Compositions for Treating Inf..
AQ
07/04REALM THERAPEUTICS : Instructions for Exchanging Ordinary Shares
PU
07/04REALM THERAPEUTICS : SEC registration effective NASDAQ listing approved
PU
06/28REALM THERAPEUTICS : Patent Issued for Methods and Compositions for Treating Inf..
AQ
06/14REALM THERAPEUTICS : Result of AGM
PU
05/31REALM THERAPEUTICS : Realm to Present at June Investor Conferences
PU
05/25REALM THERAPEUTICS : Completes Enrollment in Phase 2 Study of PR022 for Atopic D..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
2016PuriCore Successfully Completes Pre-IND Meeting With the FDA on PR022 for Ato.. 
2015#London #stocks: Puricore : #Merger #Acquisition Analysts say: skimpy Dec 201.. 
2015#London #stocks: Puricore : #Merger #Acquisition Analysts say: optimistic Aug.. 
More tweets
Qtime:3
Chart REALM THERAPEUTICS PLC
Duration : Period :
Realm Therapeutics PLC Technical Analysis Chart | PURI | GB00B3XBCR18 | 4-Traders
Technical analysis trends REALM THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Managers
NameTitle
John Alexander Martin Chief Executive Officer & Executive Director
Charles Alexander Evan Spicer Non-Executive Chairman
Marella Thorell COO, CFO, Secretary & Executive Director
Christian Peters Chief Medical Officer
Joseph William Birkett Senior Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
REALM THERAPEUTICS PLC2.70%58
CELLTRION, INC.--.--%31 997
IQVIA HOLDINGS INC9.57%22 131
LONZA GROUP9.72%21 465
INCYTE CORPORATION-25.89%14 878
SEATTLE GENETICS, INC.31.68%11 147